More than two years ago, one analyst touted Vertex’s as Gilead’s best option for a buyout that could chip in top-line growth once times got hard in hepatitis C. Now, those times are here—and that analyst is still singing the same tune.
Gilead’s best M&A option? It’s not oncology—it’s Vertex, analyst insists
Leave a Comment